G01N 33/5041
Involving analysis of members of signalling pathways
Official title: {involving analysis of members of signalling pathways}
G01N33/5041 (Involving analysis of members of signalling pathways) appears on 709 US grants and 1,275 published applications in this corpus.
Search patents in G01N- Granted patents
- 709
- Published applications
- 1,275
- Assignees
- 581
- Inventors
- 2,275
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 2 | 0 |
| 1997 | 5 | 0 |
| 1998 | 11 | 0 |
| 1999 | 15 | 0 |
| 2000 | 11 | 0 |
| 2001 | 16 | 2 |
| 2002 | 15 | 36 |
| 2003 | 16 | 58 |
| 2004 | 8 | 49 |
| 2005 | 11 | 62 |
| 2006 | 28 | 84 |
| 2007 | 31 | 65 |
| 2008 | 31 | 70 |
| 2009 | 19 | 65 |
| 2010 | 37 | 46 |
| 2011 | 48 | 65 |
| 2012 | 41 | 54 |
| 2013 | 38 | 62 |
| 2014 | 46 | 62 |
| 2015 | 34 | 63 |
| 2016 | 31 | 52 |
| 2017 | 25 | 64 |
| 2018 | 35 | 46 |
| 2019 | 31 | 56 |
| 2020 | 25 | 33 |
| 2021 | 11 | 42 |
| 2022 | 25 | 49 |
| 2023 | 18 | 26 |
| 2024 | 11 | 31 |
| 2025 | 21 | 20 |
| 2026 | 10 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Aptamer for IL-21 and use thereof7 Jul 2026US 12,674,170 B2Ribomic Inc.
- Method and system for determining intracellular mediators' activity9 Jun 2026US 12,650,424 B2Ecole Polytechnique Federale De Lausanne (Epfl)
- Biosensors for detecting arrestin signaling28 Apr 2026US 12,613,237 B2Montana Molecular LLC
- Systems and methods for measuring cell signaling protein activity31 Mar 2026US 12,590,959 B2Octant, Inc.
- KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto17 Mar 2026US 12,577,278 B2Emory University
- Selective glucocorticoid receptor modifiers for treating impaired skin wound healing1 Oct 2026US 2026/0294918 A1Akribes Biomedical GmbH
- 3-phosphoinositide biosensors20 Aug 2026US 2026/0243756 A1
- Modified g protein coupled receptor and use thereof23 Jul 2026US 2026/0209311 A1Alphelix Biotech Co., Ltd.
- Abcb5 ligands and substrates2 Jul 2026US 2026/0184810 A1Children's Medical Center Corporation
- Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases18 Jun 2026US 2026/0166125 A1St. Jude Children?S Research Hospital
Most cited
By later US patents
- Patient classification703US 6,763,307 B2Bioseek, Inc. · 2004
- Cells for drug discovery294US 6,689,558 B2Sangamo BioSciences, Inc. · 2004
- Proteolysis targeting chimeric pharmaceutical167US 7,041,298 B2California Institute of Technology · 2006
- Methods and systems for monitoring intracellular binding reactions127US 6,379,884 B2Caliper Technologies Corp. · 2002
- G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof125US 5,939,320 ANew York University · 1999